| Attribute | Value |
|---|---|
| Symbol | SLC16A1 |
| Full Name | Solute Carrier Family 16 Member 1 |
| Aliases | MCT1, Monocarboxylate Transporter 1 |
| Chromosomal Location | 1p13.3 |
| NCBI Gene ID | 6566 |
| OMIM | 109580 |
| Ensembl ID | ENSG00000146411 |
| UniProt ID | P53985 |
| Associated Diseases | AD, PD, Lactate Shuttle Deficit, Cancer Metabolism |
SLC16A1 encodes Monocarboxylate Transporter 1 (MCT1), a critical membrane transporter that mediates the facilitated diffusion of monocarboxylates such as lactate, pyruvate, ketone bodies, and acetate across the plasma membrane 1. MCT1 is a member of the major facilitator superfamily (MFS) and functions as a proton-coupled symporter, moving monocarboxylate anions together with H+ ions across the cell membrane 2.
The significance of SLC16A1 in brain function and neurodegeneration has become increasingly apparent. The transporter is essential for the "lactate shuttle" between neurons and astrocytes, a fundamental process in brain energy metabolism that has been implicated in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative conditions 3. Understanding MCT1 function provides critical insights into how the brain manages energy substrates and how this may go wrong in disease.
The human SLC16A1 gene is located on chromosome 1p13.3 and spans approximately 14 kb. The gene contains 5 coding exons and encodes a protein of 500 amino acids with a molecular weight of approximately 54 kDa 4.
MCT1 is a typical MFS transporter with 12 transmembrane α-helices connected by alternating extracellular and intracellular loops. Key structural features include:
The crystal structure of related MCT transporters has revealed the conformational changes underlying the alternating access transport mechanism 5.
SLC16A1/MCT1 exhibits a distinctive expression pattern in the brain:
Beyond the brain, MCT1 is expressed in:
The lactate shuttle, first proposed by Brooks (1998), describes how lactate produced by glycolysis in astrocytes is transported via MCT1/MCT4 and taken up by neurons as an alternative energy substrate 8. This process is critical for several reasons:
MCT1 plays a dual role in brain lactate metabolism:
The "lactate shuttle" is not merely a metabolic curiosity but a fundamental feature of brain energy metabolism that supports synaptic activity, memory formation, and overall brain function 9.
In addition to lactate, MCT1 transports ketone bodies (β-hydroxybutyrate and acetoacetate), which become important energy substrates during fasting, ketogenic diet, or in certain pathological conditions. Ketone metabolism via MCT1 is particularly important for brain function when glucose utilization is impaired 10.
MCT1 dysfunction is increasingly recognized as a contributor to AD pathogenesis:
Energy Metabolism Impairment: Early in AD, there is evidence of altered MCT1 expression and function in brain, contributing to hypometabolism observed in PET studies 11
Amyloid-β Effects: Amyloid-β peptides directly inhibit MCT1 function, reducing lactate transport and disrupting the astrocyte-neuron energy coupling 12
Tau Pathology: Hyperphosphorylated tau affects astrocyte function, including MCT1 expression, exacerbating metabolic dysfunction 13
Neurovascular Coupling: MCT1 in endothelial cells contributes to neurovascular coupling, which is impaired in AD 14
Insulin Resistance: Brain insulin resistance, a feature of AD, is associated with decreased MCT1 expression and function 15
MCT1 involvement in PD includes several mechanisms:
Dopaminergic Neuron Metabolism: MCT1 is expressed in substantia nigra dopamine neurons, where it supports their high energy demands 16
Mitochondrial Dysfunction: In PD, where mitochondrial dysfunction is prominent, altered MCT1 expression may compound energy deficits 17
Alpha-Synuclein Effects: Alpha-synuclein aggregation may affect MCT1 expression and function in PD 18
Neuroinflammation: Inflammatory processes in PD can alter MCT1 expression in both neurons and astrocytes 19
LRRK2 Connection: Mutations in LRRK2, a major genetic cause of familial PD, may affect cellular metabolism including MCT1 function 20
MCT1 alterations have been documented in ALS:
Motor Neuron Metabolism: Altered MCT1 expression in motor neurons may contribute to their vulnerability 21
Astrocyte Dysfunction: Astrocyte MCT1 dysfunction may impair metabolic support to motor neurons 22
Energy Crisis: Overall, ALS involves energy metabolism deficits in which MCT1 plays a role 23
MCT1 is critically involved in stroke pathophysiology:
Lactate Clearance: Following ischemia, MCT1-mediated lactate clearance becomes essential for recovery 24
Reperfusion Injury: MCT1 function affects tissue survival during reperfusion
Neuroprotective Strategies: Enhancing MCT1 expression may improve outcomes after stroke 25
Understanding MCT1 function in neurodegeneration opens therapeutic avenues:
Metabolic Enhancement: Compounds that enhance MCT1 expression or activity may improve brain energy metabolism 26
Ketogenic Diet Support: MCT1-mediated ketone transport supports the therapeutic use of ketogenic diets in neurodegenerative diseases 27
Lactate-Based Therapies: Lactate administration may benefit neurodegeneration through MCT1-dependent mechanisms 28
Biomarker Potential: MCT1 expression in peripheral cells may serve as a biomarker for brain energy metabolism status 29
Drug Development: Small molecules that target MCT1 are being developed for various applications 30
SLC16A1 expression is regulated by:
Several SNPs in the SLC16A1 gene have been studied:
While SLC16A1 is not a major monogenic disease gene, variants may contribute to:
Current research focuses on: